Compare Hormel Foods Corp (HRL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Revvity Inc — how do they compare? Hormel Foods Corp trades at $20.81 (market cap $11.46B), while Revvity Inc trades at $143.45 (market cap $16.01B). The key difference: Revvity Inc is the larger of the two by market cap, and Hormel Foods Corp pays the higher dividend (5.62%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Revvity Inc for 11 Days on average.
| HRL | RVTY | |
|---|---|---|
Market Cap | $11.46B | $16.01B |
Volume | 10,060,897 | 3,321,311 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $146.73 |
52-Week Low | $19.74 | $82.26 |
Typical Hold Time | 99 Days | 11 Days |
Enterprise Value | $13.45B | $18.33B |
Dividend Yield | 5.62% | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $20.81, up 0.22% today, with bearish technical signals but strong dividend credentials. The stock shows mixed fundamentals with declining net income margins (2.82% in 2025) despite recent earnings beats. Analyst consensus is cautious with 57% hold ratings, though the $24.67 price target suggests 18.5% upside potential. Recent Q3 2026 earnings beat expectations with $0.37 EPS, though organic sales declined 2% amid consumer caution.
HRL offers income investors a secure 5.5% yield with 50+ years of dividend growth, but faces headwinds from muted volume growth and margin pressures. The protein-focused portfolio provides resilience, though competitive pressures and inflation remain challenges. Technical indicators suggest near-term weakness, while fundamental recovery depends on sales stabilization and cost management execution.
RVTY trades at $143.45, down 2.24% today, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights the acquisition of Human Cell Design to expand metabolic disease research capabilities. Revenue remains stable around $2.9 billion, though net income dipped slightly in 2026.
Outlook is mixed: strong analyst support (51.72% buy ratings) and institutional interest contrast with a high P/E ratio of 68.97, suggesting premium valuation. Key risks include execution of growth initiatives and competitive pressures in healthcare. The stock's current price exceeds the consensus target of $124.00, indicating potential near-term resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
